Mixed picture for UK pharma as AstraZeneca top pick at Credit Suisse while GlaxoSmithKline knocked by Barclays downgrade
The UKs blue-chip pharma firms saw divergent fortunes on Thursday as AstraZeneca PLC (LON:AZN) was selected as a top pick by analysts as Credit Suisse while GlaxoSmithKline PLC (LON:GSK) suffered a downgrade from Barclays.
In their note on the pharma sector, Credit Suisse, which also upped AZNs target price to 8,500p from 8,200p, said the firms “top-line growth and underlying margin potential” made it the top company in its assessments, adding that the company had scored “particularly well” in its replacement power due to its product pipeline, as well as growth from new drug launches and its marketing burden, where an increased focus on oncology meant additional growth did not require significant extra investment on top of existing brands.
GSK was less lucky, with Barclays downgrading the firm to underweight from neutral in its own sector note, however its target price was retained at 1,650p.
US election possible risk over drug pricing
Looking at the sector in general, both banks highlighted that the upcoming US elections in November could prove a risk for the pharma industry, particularly with the issue of drug prices in the US proving a hot button issue, particularly in the Democratic primaries.
“In a US presidential election year, we expect political rhetoric on drug pricing to remain high”, Credit Suisse said, although they added that the chances of meaningful legislation making through the US Congress this year was low as Deomcrats will be “unlikely to endorse bipartisan efforts for changes that would give President Trump a victory to leverage on the election campaign”.
However, the bank cautioned that lowering drug prices was still a key priority among US voteRead More – Source